Kwality Pharmaceuticals delivered a robust start to FY27, with consolidated revenue surging 46% year-on-year to ₹162 crore from ₹112 crore in Q1FY26, driven by strong execution and an expanding regulatory footprint. Net profit after tax (PAT) more than doubled, rising 119% YoY to ₹26 crore from ₹12 crore, while EBITDA grew 13% to ₹41 crore. The company also raised its full-year guidance for FY27, projecting revenue of over ₹700 crore and PAT of at least ₹109 crore, reflecting management’s confidence in sustained growth momentum.

Financial Performance Highlights

The Q1FY27 results demonstrate significant top-line and bottom-line expansion compared to the previous year. The table below outlines the key financial metrics for the quarter ended June 30, 2026:

On a sequential basis, revenue increased by 3% from ₹157 crore in Q4FY26, while PAT remained stable with a 3% quarter-on-quarter growth. The expansion in EBITDA margin to 25.3% from 21.9% in the year-ago period underscores improved operating leverage and a stronger product mix.

Raised FY27 Guidance

Building on the strong performance in FY26 and the positive start to FY27, Kwality Pharmaceuticals has revised its annual guidance upwards across all key metrics. Management now targets:

• Revenue: ₹700+ crore, representing a year-on-year growth of over 39%.
• EBITDA: ₹189–196+ crore, implying an EBITDA margin of 27–28%+.
• PAT: ₹109+ crore, corresponding to a net profit margin of approximately 15.5%+.

These projections indicate a continued focus on high-margin segments and operational efficiency.

Regulatory and R&D Milestones

During the quarter, the company advanced its research and development pipeline by completing 13 Bioequivalence (BE) studies as part of its 40-molecule BE programme. This includes seven studies from the General unit, two from Beta Lactam, and four from Oncology. Filings for these completed studies have already been submitted in over 15 countries, reinforcing the company’s push into regulated markets.

Additionally, Kwality Pharmaceuticals secured more than 15 new key product registrations in Malaysia, Algeria, Peru, and Mexico. On the biologics front, the company received approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate alongside Erythropoietin, which has progressed to the clinical trial stage. Construction of the Hormone manufacturing facility remains on schedule, with completion anticipated by November 2026.

What the Numbers Show

The disproportionate jump in net profit (119%) relative to revenue growth (46%) and EBITDA growth (13%) highlights significant operating leverage and cost discipline. The expansion in PAT margins from 11% to 16% suggests that fixed costs are being spread over a larger revenue base, while variable costs are being managed effectively. This margin expansion is a key driver of the raised full-year guidance, indicating that profitability improvements are likely to persist even if revenue growth moderates slightly in subsequent quarters.